Effect of oxidative stress induced by L-dopa on endogenous antioxidants in PC-12 cells

Annals of the New York Academy of Sciences

Volumn 1074, Issue , 2006, Pages 330-336

  Vatassery, Govind T ^a   Smith, W Ed ^b   Quach, Hung T ^b  

^a VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

Antioxidants; Dopamine; L dopa; Vitamin C; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CATECHOLAMINE; DOPAMINE; LEVODOPA;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; CATECHOLAMINE SYNTHESIS; CONFERENCE PAPER; DOPAMINE BRAIN LEVEL; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; RAT;

EID: 33749565999     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1369.030     Document Type: Conference Paper

References (17)

1. HACHINSKI, V. 2000. Levodopa toxicity. Arch. Neurol. 57: 410.
2. EVANS, A.H. & A.J. LEES. 2004. Dopamine dysregulation syndrome in Parkinson's disease. Curr. Opin. Neurol. 17: 393-398.
3. LAWRENCE, A.D., A.H. EVANS & A.J. LEES. 2003. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry. Lancet Neurol. 2: 595-604.
4. FORNAI, F., P. LENZI, M. GESI, et al. 2004. Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J. Neurochem. 88: 114-123.
5. OFFEN, D., A. HOCHMAN, S. GORODIN, et al. 1999. Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis. Adv. Neurol. 80: 265-269.
6. ASANUMA, M., I. MIYAZAKI, F.J. DIAZ-CORRALES & N. OGAWA. 2004. Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinon's disease and neurotoxin-induced Parkinsonism. Acta Med. Okayama 58:221-233.
7. JOHNSON, E.A., A.A. SHVEDOVA, E. KISIN, et al. 2002. d-MDMA during vitamin E deficiency: effects on dopaminergic neurotoxicity and hepatotoxicity. Brain Res. 933: 150-163.
8. SHANKARAN, M., Y. YAMAMOTO & G.A. GUDELSKY. 2001. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse 40: 55-64.
9. MARGOLIS, S.A. 1988. Stabilization of ascorbic acid in plasma, and its liquid Chromatographic determination. Clin. Chem. 34: 2217-2223.
10. VATASSERY, G.T., W.E. SMITH & H.T. QUACH. 1993. A liquid Chromatographic method for the simultaneous determination of alpha tocopherol and tocopherolquinone in human red blood cells and other biological samples where tocopherol is easily oxidized during sample treatment. Anal. Biochem. 214: 426-430.
11. MARKWELL, M.A.K., S.M. HAAS, L.L. BIEBER & N.B. TOLBERT. 1978. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87: 206-210.
12. NYHOLM, D., H. LENNERNAS, C. GOMES-TROLIN & S.M. AQUILONIUS. 2002. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin. Neuropharmacol 25: 89-96.
13. RODRIGUEZ-MARTIN, E., S. CANALS, M.J. CASAREJOS, et al. 2001. L-Dopa and glia-conditioned medium have additive effects on tyrosine hydroxylase expression in human catecholamine-rich neuroblastoma NB69 cells. J. Neurochem. 78: 535-545.
14. RICE, M.E. 2000. Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci. 23: 209-216.
15. REBEC, G.V. & C. PIERCE. 1994. A vitamin as a modulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission. Prog. Neurobiol. 43: 537-565.
16. CORONA-MORALES, A.A., A. CASTELL, A. ESCOBAR, et al. 2003. Fullerene C60 and ascorbic acid protect cultured chromaffin cells against levodopa toxicity. J. Neurosci. Res. 71: 121-126.
17. WINKLER, B.S., S.M. ORSELL & T.S. REX. 1994. The redox couple between glutathione and ascrobic acid: a chemical and physiological perspective. Free Rad. Biol. Med. 17: 333-349.